GlaxoSmithKline (GSK) has signed an agreement with the World Health Organization (WHO) to donate 50 million doses of its adjuvanted pandemic H1N1 influenza vaccine to developing countries.

In addition to the donations, which will begin by the end of November, GSK will also be making the vaccine available under a tiered pricing policy based on WHO guidelines for some of the poorest developing countries.

GSK CEO Andrew Witty said that the company’s commitment recognises the needs of developing countries.

“This donation of 50 million doses will enable vaccination to begin soon in some of the world’s poorest countries,” said Witty.

In total GSK has allocated 20% of overall production from its Canadian manufacturing site to developing countries.

The company is also in talks with the WHO to develop a tiered pricing policy for the antiviral Relenza, which is already available at not-for-profit prices to the world’s 50 least developed countries.